Evotec completed the acquisition of Rigenerand for €23m.

Evotec, a drug discovery and development company, completed the acquisition of Rigenerand, a biotechnology company, for €23m. “The Evotec Cell Accelerator gives us the opportunity to take our cell therapy business to the next level. We are extremely confident that this important addition to our EVOcells platform will enable us to progress our internal portfolio of early innovative projects. Further, the addition will allow us to enter new partnerships and support many projects towards clinical applications and onto the market in a very efficient way. This will have a significant impact to a great number of patients who are significantly under-served with the currently available treatment regimens," Werner Lanthaler, Evotec CEO.